Savara(US:SVRA) Newsfileยท2025-11-07 02:38Core Viewpoint - Rosen Law Firm is encouraging investors of Savara Inc. to secure legal counsel before the November 7, 2025 deadline related to a securities class action lawsuit [1][2]. Group 1: Class Action Details - The class action pertains to Savara securities purchased between March 7, 2024, and May 23, 2025, with a lead plaintiff deadline set for November 7, 2025 [1]. - Investors who purchased Savara securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Savara made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [5]. - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that the public statements made by the defendants were materially false and misleading [5].